Lokon Pharma Initiates a Collaboration with Affibody to Develop Novel Cancer Therapeutics

Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses, today announced a collaboration with Affibody AB to develop a novel therapeutic strategy to treat cancer.

“Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already have one virus in clinical development, LOAd703, and we are expanding our pipeline to meet the demand of different types of malignancies” says Dr. Angelica Loskog, CEO of Lokon Pharma.  She adds, “Affibody’s proprietary antibody mimetics are small proteins with high affinity to desired targets and well suited to combine with our LOAd platform viruses. We are excited to initiate this new collaboration aiming to develop a novel treatment regime for selected cancer indications”.

“We are enthusiastic about investigating this potential extension of our Affibody^® technology platform by collaborating with leading researchers in the oncolytic virus field”, says Prof. Fredrik Frejd, CSO of Affibody. “The small size of and potential for high affinity makes Affibody^® molecules highly interesting tools for a novel treatment regime with adenovirus platforms”.

About Affibody

Affibody is a clinical stage biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody^® molecules and Albumod^®.

The company operates a focused experimental medicine model and currently has two clinical stage programs. The first is izokibep that targets autoimmune diseases. The second program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

Affibody AB is a holding of Patricia Industries.

Further information can be found at: www.affibody.com